Effect of the presence of t(11;14) for patients with AL amyloidosis treated with Bortezomib-containing regimens: Experience from the Amyloidosis Program of Calgary

Systemic light-chain amyloidosis (AL amyloidosis) is a proliferative clonal plasma cell disease caused by misfolded proteins forming toxic amyloid light-chain fibrils leading to organ damage.1 The backbone of treatment for transplant-ineligible AL amyloidosis has traditionally involved bortezomib-containing regimens (BCR).2,3 Recent studies involving AL amyloidosis have shown certain cytogenetic aberrations including t(11;14), are associated with sub-optimal responses to bortezomib and perhaps more novel agents such as daratumumab and venetoclax may yield better responses.

Source: Clinical Lymphoma, Myeloma and Leukemia - July 17, 2023 Category: Hematology Authors: Ellen Lewis, Sylvia McCulloch, Etienne Mahe, Nizar Bahlis, Paola Neri, Jason Tay, Peter Duggan, Victor H Jimenez-Zepeda Tags: Letter to the Editor Source Type: research